Venetoclax adverse event monitoring: a safety meta-analysis of randomized controlled trials and a retrospective evaluation of the FAERS

被引:0
作者
Favas, K. T. Muhammed [1 ]
Semwal, Maneesh [1 ]
Yoosuf, Beema T. [1 ]
Lad, Deepesh [2 ]
Bansal, Dipika [1 ]
机构
[1] Natl Inst Pharmaceut Educ & Res NIPER, Dept Pharm Practice, Sas Nagar Mohali 160062, Punjab, India
[2] Univ British Columbia, Dept Med, Leukemia BMT Program British Columbia, Div Hematol, Vancouver, BC, Canada
关键词
Venetoclax; Leukemia; Safety; Adverse events; Pharmacovigilance; CHRONIC LYMPHOCYTIC-LEUKEMIA; ACUTE MYELOID-LEUKEMIA; OPEN-LABEL; OBINUTUZUMAB; AZACITIDINE; MULTICENTER; RITUXIMAB; DATABASE; CLL;
D O I
10.1007/s00277-024-05676-1
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Concerns persist about venetoclax's long-term safety in larger populations, with limited evidence of infrequent and delayed adverse events (AEs). The study integrated safety data on venetoclax in leukemia patients from randomized controlled trials (RCTs) and FDA adverse event monitoring system (FAERS). We systematically reviewed RCTs reporting safety outcomes of venetoclax in adult leukemia patients of any gender, either monotherapy or in combination, applying advanced search on databases like PubMed, EMBASE, and ClinicalTrial.gov. The quality assessment was done using the Cochrane Risk of Bias Tool. We utilized a random effect meta-analysis to calculate risk ratio (RR) with 95% confidence intervals (CI). The Open Vigil 2.1 MedDRAv24 was used to search the FAERS database, with data available until September 2023. The disproportionality was calculated using the proportional reporting ratio and the reporting odds ratio. The study protocol for meta-analysis was registered with PROSPERO; CRD42022378006. For the safety meta-analysis, seven RCTs with available AEs were examined. A total of 942 AEs were found associated with the venetoclax group; 79% of them were in grade three or above. Venetoclax significantly increased the risk of neutropenia grade three or above (RR = 1.34, 95% CI: 1.10-1.64, p: 0.0033) compared with the control group. In FAERS, 26,436 patients were reported with AEs associated with venetoclax. Significant signal scores were observed in hematological, cardiac, vascular, and gastrointestinal disorders. 11 out of 30 generated signals, failed to meet the signal criteria upon refinement. The current study updated and improved the safety profile of venetoclax in the post-marketing period, assisting in risk evaluation and mitigation for the best possible patient health care.
引用
收藏
页码:3179 / 3191
页数:13
相关论文
共 42 条
  • [1] Al-Sawaf O, 2020, LANCET ONCOL, V21, P1188, DOI 10.1016/S1470-2045(20)30443-5
  • [2] Venetoclax-containing regimens in acute myeloid leukemia
    Aldoss, Ibrahim
    Pullarkat, Vinod
    Stein, Anthony S.
    [J]. THERAPEUTIC ADVANCES IN HEMATOLOGY, 2021, 12
  • [3] [Anonymous], MET OPT NONC LOW DOS
  • [4] [Anonymous], AZ COMB LOW DOS INT
  • [5] [Anonymous], STUD COMB IBR PLUS V
  • [6] [Anonymous], 2020, FDA Grants Regular Approval to Venetoclax in Combination for Untreated Acute Myeloid Leukemia
  • [7] Venetoclax: A Review in Previously Untreated Chronic Lymphocytic Leukaemia
    Blair, Hannah A.
    [J]. DRUGS, 2020, 80 (18) : 1973 - 1980
  • [8] Meta-Analysis and Subgroups
    Borenstein, Michael
    Higgins, Julian P. T.
    [J]. PREVENTION SCIENCE, 2013, 14 (02) : 134 - 143
  • [9] Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy
    Coutre, Steven
    Choi, Michael
    Furman, Richard R.
    Eradat, Herbert
    Heffner, Leonard
    Jones, Jeffrey A.
    Chyla, Brenda
    Zhou, Lang
    Agarwal, Suresh
    Waskiewicz, Tina
    Verdugo, Maria
    Humerickhouse, Rod A.
    Potluri, Jalaja
    Wierda, William G.
    Davids, Matthew S.
    [J]. BLOOD, 2018, 131 (15) : 1704 - 1711
  • [10] Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic, Version 2.2021
    Daly, Mary B.
    Pal, Tuya
    Berry, Michael P.
    Buys, Saundra S.
    Dickson, Patricia
    Domchek, Susan M.
    Elkhanany, Ahmed
    Friedman, Susan
    Goggins, Michael
    Hutton, Mollie L.
    Karlan, Beth Y.
    Khan, Seema
    Klein, Catherine
    Kohlmann, Wendy
    Kurian, Allison W.
    Laronga, Christine
    Litton, Jennifer K.
    Mak, Julie S.
    Menendez, Carolyn S.
    Merajver, Sofia D.
    Norquist, Barbara S.
    Offit, Kenneth
    Pederson, Holly J.
    Reiser, Gwen
    Senter-Jamieson, Leigha
    Shannon, Kristen Mahoney
    Shatsky, Rebecca
    Visvanathan, Kala
    Weitzel, Jeffrey N.
    Wick, Myra J.
    Wisinski, Kari B.
    Yurgelun, Matthew B.
    Darlow, Susan D.
    Dwyer, Mary A.
    [J]. JOURNAL OF THE NATIONAL COMPREHENSIVE CANCER NETWORK, 2021, 19 (01): : 77 - 102